期刊文献+

载阿托伐他汀钙的普朗尼克/mPEG-b-PLGA混合胶束 被引量:1

Atorvastatin calcium-loaded pluronic/mPEG-b-PLGA mixed micelles
下载PDF
导出
摘要 目的研究普朗尼克/mPEG-b-PLGA混合胶束中两载体配比对载阿托伐他汀钙聚合物胶束性能的影响。方法制备不同配比的mPEG-b-PLGA、F127载阿托伐他汀钙聚合物混合胶束,用激光粒度分析仪(DLS),稳态荧光光谱仪,紫外分光光度计(UV)等对其粒径、临界胶束浓度、载药量以及体外释放的性质进行了考察。结果混合胶束在载药量、稳定性等方面都由于单一普朗尼克胶束,通过药物体外释放试验比较,在24h时,混合胶束的释放量明显提高,药物更完全的释放。结论在普朗尼克载阿托伐他汀钙胶束的制备中加入一定比例的mPEG-bPLGA可不同程度的提高其性能,具有一定的应用前景。 Objective Research of effect of two carrier Pluronic and mPEG-b PLGA molar ratio on the atorvastatin calcium(ATV)-loaded polymer micelles. Methods Preparation of different ratio of mPEG-b PLGA, Fl27 load of ATV polymer mixed micelles, the particle size, critical micelle concentration, drug loading content and release properties in vitro were studied by laser particle size analyzer (DLS), steady state fluorescence spectrometer, UV spectrophotometer (UV). Results ATV-PF micelles had superiorities over ATV - F micelles in drug loading content, stability and so on. From the drug release experiment in vitro, at 24h, contents of the mixed micelles drug release were significantly higher than Pluronic micelles and more completely. Conclusion Adding certain proportion of mPEG-b PLGA in preparation of ATV-loaded Pluronie mieelles can improve the properity of micelles to some extent, and has a potential application in the further.
出处 《河南大学学报(医学版)》 CAS 2015年第3期166-170,174,共6页 Journal of Henan University:Medical Science
基金 河南省教育厅科学技术研究重点项目(13A350054)
关键词 阿托伐他汀钙 普朗尼克F127 mPEG-b-PLGA 混合胶束 torvastatin calcium(ATV) Pluronic F127 mPEG-b-PLGA mixed micelles
  • 相关文献

参考文献23

  • 1Kwon G S,Kataoka K,et al.Block copolymer micelles as long-circulating drug vehicles[J].Advanced Drug Delivery Reviews,1995(16):295-309.
  • 2Kwon G S,Okano T,et al.Polymeric micelles as new drug carriers[J].Advanced Drug Delivery Reviews,1996(21):107-116.
  • 3Kwon G S,et al.Diblock copolymer nanoparticles for drug delivery[J].Critical Reviews in Therapeutic Drug Carrier Systems,1998,15(5):481-512.
  • 4Plummer R,Wilson RH,et al.A Phase I clinical study of cisplatin-incorporated polymeric micelles(NC-6004)in patients with solid tumours[J].British Journal of Cancer,2011(104):593-598.
  • 5Hamaguchi T,Matsumura Y,et al.NK105,apaclitaxelincorporating micellar nanoparticle formulation,can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel[J].British Journal of Cancer,2005(92):1240-1246.
  • 6Danson S,Ferry D,et al.Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin(SP1049C)in patients with advanced cancer[J].British Journal of Cancer,2004(90):2085-2091.
  • 7Matsumura Y,Hamaguchi T,et al.Phase I clinical trial and pharmacokinetic evaluation of NK911,a micelle-encapsulated doxorubicin[J].British Journal of Cancer,2004,91:1775-1781.
  • 8Alexandridis P,Holzwarth J F,et al.Micellization of Poly(ethy1ene oxide)-Poly(propy1ene oxide)-Poly(ethy1ene oxide)Triblock Copolymers in Aqueous Solutions:Thermodynamics of Copolymer Association[J].Macromolecules,1994(27):2414-2425.
  • 9Bose S,Roy M,et al.Recent advances in bone tissue engineering scaffolds[J].Trends Biotechnology,2012(30):546-554.
  • 10Wei Zhang,Yuan Shi,et al.Ultifunctional PluronicP123/F127mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumor[J].Biomaterials,2011(32):2894-2906.

同被引文献8

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部